enocitabine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| nucleosides antiviral or antineoplastic agents, cytarabine or azacitidine derivatives | 1012 | 55726-47-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 20 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 4.958 | Moderate | 0.71 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 13.213 | Moderate | 0.71 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 0.003 | 10^-6 cm/s | Moderate | 0.71 |
| dh-clint | Dog hepatocyte intrinsic clearance | 75.683 | uL/min/10^6 cells | Moderate | 0.71 |
| dppb | Dog plasma protein binding (% unbound) | 0.070 | % | Moderate | 0.71 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 0.010 | % | Moderate | 0.71 |
| herg | hERG pIC50 | 4.471 | pIC50 | Moderate | 0.71 |
| hh-clint | Human hepatocyte intrinsic clearance | 120.226 | uL/min/10^6 cells | Moderate | 0.71 |
| hlm-clint | Human liver microsomal intrinsic clearance | 51.168 | uL/min/mg protein | Moderate | 0.71 |
| hppb | Human plasma protein binding (% unbound) | 0.290 | % | Moderate | 0.71 |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.832 | Moderate | 0.71 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 43.152 | Moderate | 0.71 | |
| mppb | Mouse plasma protein binding (% unbound) | 0.090 | Moderate | 0.71 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.082 | Moderate | 0.71 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 0.060 | % | Moderate | 0.71 |
| rh-clint | Rat hepatocyte intrinsic clearance | 29.992 | uL/min/10^6 cells | Moderate | 0.71 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 0.010 | % | Moderate | 0.71 |
| rppb | Rat plasma protein binding (% unbound) | 0.140 | % | Moderate | 0.71 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 0.318 | uM | Moderate | 0.71 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| FDA MoA | N0000000233 | Nucleic Acid Synthesis Inhibitors |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D000998 | Antiviral Agents |
| MeSH PA | D000963 | Antimetabolites |
| MeSH PA | D000964 | Antimetabolites, Antineoplastic |
| MeSH PA | D007155 | Immunologic Factors |
| MeSH PA | D007166 | Immunosuppressive Agents |
| FDA EPC | N0000175595 | Nucleoside Metabolic Inhibitor |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:35221 | antimetabolite |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:35705 | immunosuppressive agent |
| CHEBI has role | CHEBI:38068 | antimalarial |
| CHEBI has role | CHEBI:50249 | anticoagulant |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
| CHEBI has role | CHEBI:233423 | antifibrotic agent |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.91 | acidic |
| pKa2 | 12.42 | acidic |
| pKa3 | 12.58 | acidic |
| pKa4 | 13.11 | acidic |
| pKa5 | 1.62 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D01633 | KEGG_DRUG |
| 4018080 | VANDF |
| C0059364 | UMLSCUI |
| CHEBI:31537 | CHEBI |
| AR3 | PDB_CHEM_ID |
| CHEMBL2106589 | ChEMBL_ID |
| C015019 | MESH_SUPPLEMENTAL_RECORD_UI |
| 5121 | INN_ID |
| 9YVR68W306 | UNII |
| 71734 | PUBCHEM_CID |
| 3041 | RXNORM |
| 372 | MMSL |
| 4526 | MMSL |
| d00201 | MMSL |
| 002649 | NDDF |
| 010917 | NDDF |
| 387511003 | SNOMEDCT_US |
| 89265009 | SNOMEDCT_US |
| C0010711 | UMLSCUI |
| DB00987 | DRUGBANK_ID |
| 6253 | PUBCHEM_CID |
| 1709 | INN_ID |
| D003561 | MESH_DESCRIPTOR_UI |
| CHEBI:28680 | CHEBI |
Pharmaceutical products:
None